Global Antivenom Market Growth 2019-2024

Antivenom, also known as antivenin, venom antiserum and antivenom immunoglobulin, is a medication made from antibodies which is used to treat certain venomous bites and stings. They are only recommended if there is significant toxicity or a high risk of toxicity. The specific antivenom needed depends on the species involved. It is given by injection.
Asia-Pacific Antivenom market is valued at 285.00 million USD in 2017 and is expected to reach 359.23 million USD by the end of 2023, growing at a CAGR of 43.93% between 2016 and 2022.
The price of Antivenom is slightly increased in nearly five years. For being accorded with the corresponding application area, the product price has a large differences.
Despite the presence of competition problems, due to the global recovery trend is clear, investors are still optimistic about this areas, the future will still have more new investment enter the field.

According to this study, over the next five years the Antivenom market will register a 2.5% CAGR in terms of revenue, the global market size will reach US$ 960 million by 2024, from US$ 830 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Antivenom business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of Antivenom market by product type, application, key manufacturers and key regions and countries.

This study considers the Antivenom value and volume generated from the sales of the following segments:

Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
Polyvalent antivenom
Monovalent antivenom
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
Retail Pharmacies
Hospitals
Others

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
CSL Behring
Merck & Co.
BTG Plc
Pfizer
Haffkine Bio-Pharmaceutical Corporation
Rare Disease Therapeutics
Flynn Pharma
Vins Bioproducts
Bharat Serums and Vaccines
Serum Biotech

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Antivenom consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Antivenom market by identifying its various subsegments.
Focuses on the key global Antivenom manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Antivenom with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Antivenom submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.